Combination of Tumor Necrosis Factor α and Interleukin-6 Induces Mouse Osteoclast-like Cells With Bone Resorption Activity Both In Vitro and In Vivo

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Serum interleukin‐6 levels in response to methotrexate treatment in psoriatic patients

(2012) Tamilselvi Elango et al.   CLINICA CHIMICA ACTA

Tetracyclines Convert the Osteoclastic-Differentiation Pathway of Progenitor Cells To Produce Dendritic Cell-like Cells

(2012) S. Kinugawa et al.   JOURNAL OF IMMUNOLOGY

The osteoclast and its unique cytoskeleton

(2011) Steven L. Teitelbaum   Annals of the New York Academy of Sciences

IL-1  and TNF -initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis

(2011) T. Mori et al.   INTERNATIONAL IMMUNOLOGY

Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains

(2009) Neal K. Williams et al.   JOURNAL OF MOLECULAR BIOLOGY

Interleukin-6 Inhibits Receptor Activator of Nuclear Factor κB Ligand-Induced Osteoclastogenesis by Diverting Cells into the Macrophage Lineage: Key Role of Serine727Phosphorylation of Signal Transducer and Activator of Transcription 3

(2008) Laurence Duplomb et al.   ENDOCRINOLOGY

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH